<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93958">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01737255</url>
  </required_header>
  <id_info>
    <org_study_id>CCR3802</org_study_id>
    <nct_id>NCT01737255</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome</brief_title>
  <acronym>SIGNIFY</acronym>
  <official_title>Magnetic Resonance Imaging Screening In Li Fraumeni Syndrome: An Exploratory Whole Body MRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <authority>United Kingdom: NHS Health Research Authority</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed at exploring the use of whole body MRI for early cancer detection in
      TP53 mutation carriers and population controls, with the hypothesis that more cancers will
      be detected in the TP53 mutation carrier group. A secondary end-point will be the number of
      incidental findings detected and subsequent investigations required. A series of
      questionnaires will be used to assess the psychological impact of screening on both the
      study and control group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Diagnosis of malignant disease</measure>
    <time_frame>Within 12 months of MRI scan</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following MRI scan further investigations may be required to diagnose malignancy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnosis of relevant non-malignant disease</measure>
    <time_frame>12 months following MRI scan</time_frame>
    <safety_issue>No</safety_issue>
    <description>Further investigations may be required following the MRI to characterise such findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnosis of non-relevant disease, number and type of investigations required</measure>
    <time_frame>12 months following MRI</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological impact of MRI screening</measure>
    <time_frame>12 months following MRI screening</time_frame>
    <safety_issue>No</safety_issue>
    <description>Psychological questionnaires to be completed at intervals up till 12 months post scan</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Li-Fraumeni Syndrome</condition>
  <arm_group>
    <arm_group_label>TP53 mutation carriers</arm_group_label>
    <description>Carriers of TP53 mutation not known to be low penetrance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population controls</arm_group_label>
    <description>Population controls will be sex and aged matched (+/- 5 years) to the TP53 mutation carrier group, with no personal history of cancer and no family history of cancer diagnosed under 50 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whole body MRI</intervention_name>
    <description>Individuals will undergo whole body and brain MRI</description>
    <arm_group_label>TP53 mutation carriers</arm_group_label>
    <arm_group_label>Population controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psychological questionnaires</intervention_name>
    <description>All recruits will complete questionnaires at 6 time points to assess psychological impact</description>
    <arm_group_label>TP53 mutation carriers</arm_group_label>
    <arm_group_label>Population controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The TP53 mutation carriers will be recruited from genetics clinics and through
        advertising.

        The population controls will be recruited through advertising
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Carrier of germline TP53 mutation which, in the view of the geneticist, is not known
             to be low penetrance OR non-related individual with no personal history of malignancy
             and no first degree relatives diagnosed with malignancy under the age of 50 years

          -  Age between 18 and 60

          -  Able to give informed consent

        Exclusion Criteria:

          -  Individual with low penetrance TP53 mutation

          -  Individual with TP53 variant of unknown significance.

          -  Previous malignancy diagnosed &lt; 5 years ago in TP53 carriers (except non-melanomatous
             skin cancer or cervical CIS) Previous history of malignancy in non-related controls
             (except non-melanomatous skin cancer or cervical CIS)

          -  Current symptoms suggestive of malignancy

          -  Contraindication to MRI (such as non-MR compatible metal implants) as specified by
             the standard MR safety checklist

          -  Claustrophobia

          -  ECOG performance status &gt;2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosalind Eeles, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Cancer Research, Surrey, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosalind Eeles, PhD</last_name>
    <phone>44 208 661 3642</phone>
    <email>rosalind.eeles@icr.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emma Killick, MBBS</last_name>
    <phone>44 208 661 3375</phone>
    <email>emma.killick@icr.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Genetics Unit, Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosalind A Eeles, FRCP FRCR</last_name>
      <phone>44 208 661 3642</phone>
      <email>rosalind.eeles@icr.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth K Bancroft, RGN MMedSci</last_name>
      <phone>44 207 808 2136</phone>
      <email>elizabeth.bancroft@icr.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 27, 2012</lastchanged_date>
  <firstreceived_date>November 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Li-Fraumeni Syndrome</keyword>
  <keyword>Whole Body Magnetic Resonance Imaging</keyword>
  <keyword>TP53</keyword>
  <keyword>Psychological Impact</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Li-Fraumeni Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
